Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation

The article presents data on the efficacy of erlotinib in the treatment of NSCLC in the presence of EGFR gene mutation. Its advantages over chemotherapy in terms of survival, quality of life, and tolerability of treatment, both as monotherapy and in combination with cytostatics and other targeted dr...

Full description

Bibliographic Details
Published in:	Медицинский совет
Main Authors:	S. V. Orlov, A. M. Lozhkina, S. V. Odintsova, M. A. Sviridenko, A. O. Cheremnykh, M. A. Urtenova, E. A. Filippova
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2019-06-01
Subjects:	lung cancer egfr mutations erlotinib
Online Access:	https://www.med-sovet.pro/jour/article/view/3054

Similar Items

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
by: Nobuhiko Seki, et al.
Published: (2019-01-01)

Erlotinib: How to increase the duration of effective use of tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation
by: E. I. Borisova, et al.
Published: (2021-08-01)

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
by: Qian Wang, et al.
Published: (2022-09-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)

Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on <i>KRAS</i> Mutation
by: Alexander Siegman, et al.
Published: (2024-07-01)

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Role of Erlotinib 100 mg/d in the Treatment of  Advanced Adenocarcinoma Lung Cancer Failed to Previous Chemotherapy
by: Chunlei SHI, et al.
Published: (2011-06-01)

Suppression of Epidermal Growth Factor Receptor by Erlotinib Attenuates Carvacrol-induced Skin Inflammation
by: Yujing Wang, et al.
Published: (2024-12-01)

Erlotinib Improves the Response of Glioblastoma Cells Resistant to Photodynamic Therapy
by: Karen Olthoff, et al.
Published: (2024-11-01)

Harnessing nanotechnology for enhanced delivery of erlotinib: a dynamic duo in cancer treatment
by: Rakesh Pahwa, et al.
Published: (2024-07-01)

Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy
by: Yuling Zhou, MS, et al.
Published: (2020-06-01)

OPTIMAL SEQUENCE OF APPLICATION OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH ACTIVATING EGFR MUTATIONS
by: A. A. Kolomeytseva, et al.
Published: (2020-12-01)

Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy
by: Kenneth K. Tanabe, et al.
Published: (2024-01-01)

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation
by: Naoya Ishibashi, et al.
Published: (2023-12-01)

Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations
by: Mirtavoos-mahyari Hanifeh, et al.
Published: (2021-12-01)

Effectiveness and safety of the bevacizumab and erlotinib combination versus erlotinib alone in EGFR mutant metastatic non-small-cell lung cancer: systematic review and meta-analysis
by: Rodrigo Motta-Guerrero, et al.
Published: (2024-01-01)

Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
by: Juhi Mody, et al.
Published: (2024-03-01)

AKR1C3 as a therapeutic target to overcome erlotinib resistance in lung adenocarcinoma
by: William C. Cho, et al.
Published: (2025-02-01)

The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
by: Demiray A, et al.
Published: (2018-12-01)

Upregulated interleukin‐6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma
by: Aditya Stanam, et al.
Published: (2015-08-01)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
by: Svenja Wagener-Ryczek, et al.
Published: (2020-05-01)

A Case Report on Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma: Treated Through a Non-surgical Approach
by: Syed Mohsin Raza, et al.
Published: (2023-06-01)

Treatment of TRPV3 mutation-associated Olmsted syndrome with erlotinib
by: Kathleen E. Spitz, MD, MBA, et al.
Published: (2022-07-01)

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies
by: Khalid Alhazzani, et al.
Published: (2023-10-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression
by: Nobutomo Ikarashi, et al.
Published: (2020-04-01)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
by: Natalie Carroll, et al.
Published: (2022-11-01)

Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
by: A. M. Lozhkina, et al.
Published: (2018-11-01)

Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib
by: Oğuzhan Yıldız, et al.
Published: (2025-10-01)

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
by: Murray Samuel, et al.
Published: (2012-09-01)

Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
by: Peng Deng, et al.
Published: (2022-01-01)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
by: Atakan Topcu, et al.
Published: (2022-10-01)

Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor
by: J. Machado-Rugolo, et al.
Published: (2023-01-01)

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study
by: Yukio Hosomi, et al.
Published: (2022-08-01)

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature
by: Kishan Soni, et al.
Published: (2020-07-01)

A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
by: Duo Wang, et al.
Published: (2022-07-01)

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
by: Yuan Gao, et al.
Published: (2017-07-01)

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
by: Amanda C. Sharko, et al.
Published: (2021-01-01)